Zur Rose completes acquisition in Germany
Frauenfeld – The Zur Rose Group is to take over the shipping activities of Apotal, the German online pharmacy. With this, the Group is seeking to expand its European client base to over 8 million customers.
Last year, Apotal generated sales of 145 million euros in the mail order business, as detailed by the Zur Rose Group in a corresponding press release. Depending on the achievement of agreed growth and profitability targets, the total purchase price could ultimately be equivalent to 0.4x the planned sales in 2020. Apotal Founder Heinz-Peter Fichter is to become a shareholder in the Zur Rose Group following the completion of this transaction.
The takeover of the shipping activities of the Apotal Group could see the Zur Rose Group gain around 1.1 million new customers. The company is therefore seeking to consolidate its market leadership in Europe and expand its client base to more than 8 million active customers, Zur Rose writes in the press release. The new acquisition should also allow the Group to improve scaling effects and generate economies of scale. Zur Rose intends to exploit these to facilitate the introduction of new digital products.
“Apotal has built a strongly performing OTC online business which we will develop further, capitalizing on our leading position in electronic prescription and ehealth services”, comments Walter Oberhänsli, CEO of Zur Rose, in the press release. “Our market and innovation leadership as a pre-eminent digital health services provider is thus strengthened”, he adds.